Funding for this research was provided by:
National Institute on Aging (U01 AG006786, R37 AG011378, K76 AG057015, P30 AG062677, RF1 AG69052)
National Institute of Neurological Disorders and Stroke (R01 NS097495)
Received: 28 September 2021
Accepted: 6 December 2021
First Online: 14 December 2021
: The study was approved by Mayo Clinic and Olmsted Medical Center Institutional Review Boards. Written informed consent was obtained from all participants.
: Not applicable
: Dr. Knopman served on a Data Safety Monitoring Board for the DIAN study. He serves on a Data Safety monitoring Board for a tau therapeutic for Biogen, but receives no personal compensation. He is a site investigator in the Biogen aducanumab trials. He is an investigator in a clinical trial sponsored by Lilly Pharmaceuticals and the University of Southern California. He serves as a consultant for Samus Therapeutics, Third Rock, Roche and Alzeca Biosciences but receives no personal compensation. Dr. Lowe serves on scientific advisory boards for Bayer Schering Pharma, Philips Molecular lmaging, Life Molecular lmaging, AVID Radiopharamceuticals, and GE Healthcare and receives research support from GE Healthcare, Siemens Molecular Imaging, and AVID Radiopharmaceuticals. Dr. Jack serves on an independent data monitoring board for Roche, has served as a speaker for Eisai, and consulted for Biogen, but he receives no personal compensation from any commercial entity. Dr. Petersen is a consultant for Roche, Biogen, Merck, Eli Lilly, and Genentech. He receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003). Dr. Mielke is a consultant for Biogen, Brain Protection Company, and LabCorp on blood-based biomarkers. She serves on Editorial Boards for <i>Alzheimer’s and Dementia</i>, <i>Neurology</i>, and <i>Alzheimer’s Research Therapy</i>. All other authors report no conflicts of interest.